RT Journal Article
SR Electronic
T1 Pre-existing conditions are associated with long-COVID patients’ hospitalization, despite confirmed clearance of SARS-CoV-2 virus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.28.20221655
DO 10.1101/2020.10.28.20221655
A1 Colin Pawlowski
A1 AJ Venkatakrishnan
A1 Eshwan Ramudu
A1 Christian Kirkup
A1 Arjun Puranik
A1 Nikhil Kayal
A1 Gabriela Berner
A1 Akash Anand
A1 Rakesh Barve
A1 John C. O’Horo
A1 Andrew D. Badley
A1 Venky Soundararajan
YR 2020
UL http://medrxiv.org/content/early/2020/10/30/2020.10.28.20221655.abstract
AB The current diagnostic gold-standard for SARS-CoV-2 clearance from infected patients is two consecutive negative PCR test results. However, there are anecdotal reports of hospitalization from protracted COVID complications (long-COVID) despite such confirmed viral clearance, presenting a clinical conundrum. We conducted a retrospective analysis of 266 COVID patients to compare those that were admitted/re-admitted post-viral clearance (hospitalized post-clearance cohort, n=93) with those that were hospitalized pre-clearance but were not re-admitted post-viral clearance (non-hospitalized post-clearance cohort, n=173). In order to differentiate these two cohorts, we used neural network models for the augmented curation of comorbidities and complications with positive sentiment in the EHR physician notes. In the year preceding COVID onset, acute kidney injury (n=15 (16.1%), p-value: 0.03), anemia (n=20 (21.5%), p-value: 0.02), and cardiac arrhythmia (n=21 (22.6%), p-value: 0.05) were significantly enriched in the physician notes of the hospitalized post-clearance cohort. This study highlights that these specific pre-existing conditions are associated with amplified hospitalization risk in long-COVID patients, despite their successful SARS-CoV-2 viral clearance. Our findings motivate follow-up prospective research into specific risk factors that predispose some patients towards the long-COVID syndrome.Competing Interest StatementThe authors from nference have financial interests in the company. ADB is a consultant for Abbvie, is on scientific advisory boards for Nference and Zentalis, and is founder and President of Splissen therapeutics. One or more of the investigators associated with this project and Mayo Clinic have a Financial Conflict of Interest in technology used in the research and that the investigator(s) and Mayo Clinic may stand to gain financially from the successful outcome of the research. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and is being conducted in compliance with Mayo Clinic Conflict of Interest policies.Funding StatementADB is supported by Grants AI 110173 and AI120698 from NIAID, 109593-62-RGRL from Amfar, and the HH Sheikh Khalifa Bin Zayed Al-Nahyan named professorship from Mayo Clinic.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This retrospective research was conducted under IRB 20 003278, Study of COVID-19 patient characteristics with augmented curation of Electronic Health Records (EHR) to inform strategic and operational decisions. For further information regarding the Mayo Clinic Institutional Review Board (IRB) policy, and its institutional commitment, membership requirements, review of research, informed consent, recruitment, vulnerable population protection, biologics, and confidentiality policy, please refer to www.mayo.edu/research/institutional-review-board/overview.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the paper was accessed via an IRB approved by the Mayo Clinic. Please see Methods section for details.